Is it time to redefine cisplatin ineligibility in metastatic urothelial cancer?

Affiliations

Editorial

Srikala S Sridhar. Eur J Cancer. 2020 Mar.

. 2020 Mar:127:158-159.

doi: 10.1016/j.ejca.2019.12.019. Epub 2020 Jan 31.

¹ Princess Margaret Cancer Center, University of Toronto, Canada. Electronic address: srikala.sridhar@uhn.ca.

No abstract available

Comment on

Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM).
Holmsten K, Jensen NV, Mouritsen LS, Jonsson E, Mellnert C, Agerbæk M, Nilsson C, Moe M, Carus A, Öfverholm E, Lahdenperä O, Brandberg Y, Johansson H, Hellström M, Maase HV, Pappot H, Ullén A. Holmsten K, et al. Eur J Cancer. 2020 Mar;127:173-182. doi: 10.1016/j.ejca.2019.08.033. Epub 2019 Oct 22. Eur J Cancer. 2020. PMID: 31648851 Clinical Trial.
Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16).
Park I, Kim BS, Lim HY, Kim HJ, Lee HJ, Choi YJ, Park KH, Lee KH, Yoon S, Hong B, Hong JH, Ahn H, Lee JL. Park I, et al. Eur J Cancer. 2020 Mar;127:183-190. doi: 10.1016/j.ejca.2019.08.034. Epub 2019 Oct 24. Eur J Cancer. 2020. PMID: 31668839 Clinical Trial.